NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.